Market Place
Sourcing Support
Takeda announces voluntary withdrawal of lung cancer therapy
03 Oct 2023 //
HEALTH ET
Takeda Provides Update on EXKIVITY® (mobocertinib)
02 Oct 2023 //
BUSINESSWIRE
Takeda`s Exkivity, a rival to J&J, fails in lung cancer trial
01 Aug 2023 //
FIERCE PHARMA
FoundationOne®Liquid CDx Receives FDA-Approval as a Companion for EXKIVITY
04 May 2023 //
BUSINESSWIRE
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China
11 Jan 2023 //
BUSINESSWIRE
NHS grants fast-track access to Takeda`s lung cancer drug Exkivity
22 Mar 2022 //
PHARMAPHORUM
US FDA approval tracker: September
01 Oct 2021 //
EVALUATE
U.S. FDA approves Takeda`s lung cancer therapy
17 Sep 2021 //
REUTERS
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer
18 Sep 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.